US-based life science research company Pruvn Research has published preliminary findings from a human clinical trial assessing the effects of Max International’s RiboCeine supplementation on serum glutathione levels.
The research suggests that RiboCeine could be beneficial in increasing serum glutathione levels, particularly among older individuals.
Go deeper with GlobalData
Approved by the University of Santa Catarina Ethics Committee in Brazil, the double-blinded, placebo-controlled trial involved 40 participants aged between 38 and 60 years.
The participants were randomly assigned to receive either a placebo or 250mg of RiboCeine daily for four weeks.
Their serum glutathione levels were measured using a Spectrophotometric Assay at the start and end of the trial.
While the placebo group saw a decline in serum glutathione levels, those taking RiboCeine experienced a significant 26.6% increase, with a 64.7% rise in glutathione levels registered among participants aged 51 to 60 years.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataPruvn’s scientists have proposed further studies with a larger cohort to substantiate these initial findings.
Pruvn CEO and co-founder Elias Arjan said: “When a company has already conducted preclinical trials, whether it’s animal models, cell cultures, or in silico via a computer simulation, we don’t have to worry whether the compound has an impact, but rather we can focus on its efficacy in a real-world setting, and ultimately that’s what matters most to customers.”
Researchers have carried out 55 peer-reviewed, independent trials on Max International’s patented ‘cornerstone’ compound, mainly using animal models over the past 30 years.
Max International is now focusing on human trials to further its findings and confirm the compound’s efficacy.
Max International executive chairman Joe Voyticky said: “At Max International, we are dedicated to excellence and put our products to scientific scrutiny to prove to consumers that Max has the best products on the market.”
“Consumers care about actual, legitimate proof that the products they buy are scientifically validated.”
